Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?
AffiliationClinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Healthcare Science Centre, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester, M20 4BX, UK. email@example.com.
MetadataShow full item record
AbstractThe central goal of cancer immunotherapy is to control tumors through the mobilization of the patient's immune system. Vaccines targeting the Her2/neu proto-oncogene have been tested with some early encouraging responses in breast cancer. However, a more effective set of vaccines targeting specific immune cell subtypes may provide a more potent means to stimulate anti-tumor immunity. Dendritic cell-specific antibodies fused with the Her2/neu protein proved effective at generating immune responses in preclinical models. Importantly, only low amounts of protein vaccine were required to generate this response, which has potentially significant implications for the future clinical development of Her2/neu-targeted vaccines and other vaccine targets.
CitationTargeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein? 2012, 14 (3):106 Breast Cancer Res
JournalBreast Cancer Research
- Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
- Authors: Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y
- Issue date: 2009 Jul 15
- A tat fusion protein-based tumor vaccine for breast cancer.
- Authors: Viehl CT, Becker-Hapak M, Lewis JS, Tanaka Y, Liyanage UK, Linehan DC, Eberlein TJ, Goedegebuure PS
- Issue date: 2005 Jul
- [Anti-HER2 vaccines: The HER2 immunotargeting future?].
- Authors: Ladjemi MZ, Jacot W, Pèlegrin A, Navarro-Teulon I
- Issue date: 2011 Jun
- Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
- Authors: Kim JH, Majumder N, Lin H, Chen J, Falo LD Jr, You Z
- Issue date: 2005 Jun
- HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
- Authors: Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, Riccardo F, Antonilli M, Napoletano C, Bellati F, Benedetti-Panici P, Torrisi MR, Frati L, Nuti M, Rughetti A
- Issue date: 2011 Dec